Android app on Google Play

Myriad Genetics, Inc. (MYGN) Tops Q2 EPS by 4c, Boosts Guidance

February 5, 2013 4:31 PM EST Send to a Friend
Myriad Genetics, Inc. (NASDAQ: MYGN) reported Q2 EPS of $0.42, $0.04 better than the analyst estimate of $0.38. Revenue for the quarter came in at $149.1 million versus the consensus estimate of $143.71 million.

Myriad Genetics, Inc. sees FY2013 EPS of $1.55-1.58, versus the consensus of $1.54. Myriad Genetics, Inc. sees FY2013 revenue of $575-585 million, versus prior guidance of $570-585 million and the consensus of $580.06 million.

For earnings history and earnings-related data on Myriad Genetics, Inc. (MYGN) click here.

You May Also Be Interested In

Related Categories

Earnings, Guidance

Related Entities


Add Your Comment